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Abstract objectives To explore the advantages and challenges of working with the Good Clinical Practice
(GCP)-International Conference of Harmonization (ICH) E6 guideline and its interpretation from the
perspective of clinical trial teams based in sub-Saharan Africa.
methods We conducted 60 key informant interviews with clinical trial staff at different levels in
clinical research centres in Kenya, Ghana, Burkina Faso and Senegal and thematically analysed the
responses.
results Clinical trial teams perceived working with ICH-GCP as highly advantageous and regarded
ICH-GCP as applicable to their setting and efficiently applied. Only for informed consent did some
clinical trial staff (one-third) perceive the guideline as insufficiently applicable. Specific challenges
included meeting the requirements for written and individual consent, conditions for impartial
witnesses for illiterates or legally acceptable representatives for children, guaranteeing voluntary
participation and ensuring full understanding of the consent given. It was deemed important to have
ICH-GCP compliance monitored by relevant ethics committees and regulatory authorities, without
having guidelines applied overcautiously.
conclusion Clinical trial teams in sub-Saharan Africa perceived GCP as a helpful guideline, despite
having been developed by northern organisations and despite the high administrative burden of
implementing it. To mitigate consent challenges, we suggest adapting GCP and making use of the
flexibility it offers.
keywords clinical trials, Africa South of the Sahara, good clinical practice, qualitative research,
guideline
Introduction
Clinical trials in sub-Saharan Africa (SSA) are critically
important to improving the health of local populations.
Guidelines ensure that ethical and scientific quality stan-
dards are met in clinical trials (CTs) involving humans.
History has shown the need for guidelines to protect the
trial participants [1]. Having the appropriate guideline
for scientific and procedural rigour in CTs is crucial
because of its potential impact on health policy or on
new medicines registration.
The E6 Good Clinical Practice (GCP) guideline devel-
oped by the International Conference of Harmonization
(ICH), consisting of the USA, the EU and Japan, is the
internationally accepted gold standard by which to per-
form CTs [2]. The guideline was developed emphasising
trials targeting medicines registration and without input
from resource-limited countries (RLCs) [2].
The ICH-GCP aims to protect the rights, safety and
well-being of trial subjects and to ensure the quality and
integrity of data from clinical testing. Today, many other
guidelines regulate quality, efficacy, safety and multidisci-
plinary topics beyond the ICH-GCP document. Other
agencies have also issued various guidances and position
papers [3, 4].
In industrialised countries, ICH-GCP itself is rarely
criticised [5–8]. Instead, criticism is directed towards the
interpretation of the guideline [9–11], such as the over-
interpretation that leads to inflated administration and
costs. Due to the limited validity of patents, the phar-
maceutical industry reportedly prioritises faster trials
and regulatory compliance over cost savings, risk
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adaptation and reducing complexity [12]. In contrast,
ICH-GCP states in nine instances that the guideline
should be implemented according to the risk of the trial
[2]; this risk-based notion becomes even more prominent
in the E6 integrated addendum to ICH-GCP, which is
currently undergoing consultation [13].
Additional challenges arise when applying ICH-GCP in
RLCs. First, these international standards seemed to have
been imported without considering cultural and socio-eco-
nomic contexts [14, 15]. Second, CT teams in RLCs often
have to overcome deficits in infrastructure, human
resources and health systems. An appropriate interpreta-
tion of ICH-GCP for RLCs is missing, and some research-
ers fear the enforcement of the industry standards in
RLCs as they are becoming the globally accepted practice
[12, 14, 16–19]. However, most authors think that ICH-
GCP is the right guideline for CTs in RLCs and that full
adherence to ICH-GCP [20] or at least to its core elements
[19, 21] is appropriate and should be preserved. Some
authors claim that ICH-GCP’s administrative require-
ments distract attention from the participant and are not
feasible for CT teams in RLCs [17, 21]. Along with the
ethical challenges, the guidelines need appropriate inter-
pretation in these settings [14, 17].
A reason for not applying ICH-GCP in an adapted
manner in RLCs could be that sometimes the mostly
northern sponsors [10] demand that trials in RLCs
meet all conceivable expectations of their northern reg-
ulatory authorities in terms of guidance interpretations.
Authors criticising the current trial practices in RLCs
underline that an appropriate, adapted application of
the guidelines does not equate to substandard conduct
of trials compared with wealthier countries [14, 16,
19]. These authors argue that a risk-adapted approach
is urgently needed and possible without compromising
quality [17, 21]. This debate is not supported by any
systematic research but has been introduced largely by
northern expatriates working in RLCs.
Several initiatives have tried to tackle the lack of ade-
quate CT standards in RLCs. WHO developed the
WHO-GCP, which promotes identical standards to
ICH-GCP, while the African Vaccine Regulatory Forum
(AVAREF) published a draft GCP guideline specifically
for vaccine trials in SSA. The AVAREF-GCP differs from
ICH-GCP by including a chapter Provisions and prereq-
uisites for a clinical trial that stresses the importance of
risk–benefit considerations and ethical principles includ-
ing references to ethics guidelines. A common platform
for clinical researchers in RLCs, the ‘global health trials’
community, hosts discussions about GCP application
[22]. Round table discussions concluded that ICH-GCP
guidelines are ‘non-negotiable’ and equally applicable in
the north and the south. They recommend to coherently
establish ethical reviews in the sponsor’s country and
locally, plus Data and Safety Monitoring Boards. Ethical
challenges such as informed consent and standards of
care were also discussed [23, 24], whereas the develop-
ment of general recommendations on this sensitive topic
was regarded as being difficult [23]. At a more detailed
level, Hanna et al. [20] developed quality indicators to
assess ICH-GCP compliance in trials in RLCs, while
Kuepfer and Burri [25] listed minimal standards. Lang
and Siribaddana [14] highlighted where the guideline
might be overcautiously applied, and Acosta et al. [18]
reported challenges of implementing the 13 principles of
GCP in RLCs.
Nevertheless, guidance on risk- and context-adapted
application of ICH-GCP in RLCs is still missing, prompt-
ing CT teams and sponsors to devise their own
approaches. Our team has faced similar operational chal-
lenges over the past 20 years, and we agree with Lang
et al. [16] that local CT teams must be involved in the
debate on guideline application.
The study investigates advantages and challenges of
working with ICH-GCP and examines whether the guide-
line is being applied in an RLC-adapted and efficient
manner in the perception and experience of trial staff
working in RLCs in SSA. Among the wealth of regula-
tions, ICH-GCP is the accepted gold standard in most
SSA countries although the extent to which it has been
integrated into national laws varies. In the remainder of
the document, ‘guideline’ and ‘GCP’ always refers to
ICH-GCP E6, while ‘authority’ refers to regulatory
authorities and ethics committees.
Methods
To compare different language regions in SSA, clinical
research centres were chosen in two English-speaking
(Kenya and Ghana) and two French-speaking African
countries (Burkina Faso and Senegal). These four coun-
tries were selected as they contribute substantially to
health research activities in SSA and cover western and
eastern regions [26]. In each country, we contacted all
the major clinical research centres with a focus on pov-
erty-related diseases and a track record of completed CTs
(no more than four such centres could be identified per
country). In every country, we selected the first two
research centres that agreed to our visit. In English-speak-
ing African countries, one semi-urban, one urban and
two rural clinical research centres were visited, and in
French-speaking African countries, one rural and three
urban research centres were visited. Two of the urban
centres frequently conducted trials in the rural area too.
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The names of the centres have been withheld to ensure
anonymity of the interviewees. Interviews were open to
all investigators, study coordinators, clinicians and pro-
fessionals working in quality assurance in the centre with
at least half-a-year experience in clinical research. In each
centre, the sample was drawn with the assistance of one
clinical trial staff member, who approached eligible par-
ticipants and informed them about the study.
Sixty key informant interviews were conducted
(Table 1). The majority of the interviewees were exclu-
sively working in clinical research without involvement in
routine health care. To develop the interview guide, NV
reviewed the literature and conducted preliminary inter-
views with clinical researchers working in RLCs and
developed countries. Based on these results, NV gener-
ated the interview guide together with three experienced
clinical researchers and a social scientist. We selected the
interview questions which best encouraged interviewees
to openly speak about applicability and efficiency of
guideline implementation. The interview guide was pre-
tested and developed iteratively as data emerged. It con-
sisted of general questions about quality, guidelines, chal-
lenges and perceived inefficiencies in CTs. In Kenya and
Ghana, interviews were conducted in English. The
interview guide was then translated into French, which
included a back-translation and review of terminologies.
Subsequently, interviews in Burkina Faso and Senegal
were conducted in French.
After having explained the purpose of the study and
informed the participants of their right to withdraw from
the study at any given time, participants gave either oral
consent (Kenya) or written consent (Ghana, Burkina
Faso, and Senegal).
Between 13 and 17 interviews were conducted in each
country between 2014 and 2015. After the first 11 inter-
views in each country, saturation of information was
reached with few or no new concepts raised [27]. Inter-
views were tape-recorded and transcribed verbatim (by
NV, AJ, SK, AK). Data were analysed in MAXQDA 11,
using thematic analysis as per Braun and Clarke [28].
NV and AJ coded independently, with a focus on guideli-
nes, administration and inefficiencies in CTs. The coding
framework was discussed before agreeing on a final ver-
sion. Key themes were cross-tabulated to explore differ-
ences between countries and staff levels.
Ethical review exemptions were granted by the Ethics
Committee of Northwest and Central Switzerland and
the Pharmacy and Poisons Board in Kenya, as the
research project was not involving access to or collection
of private or sensitive data. Ethical clearance was
obtained in Ghana, Burkina Faso and Senegal, as the sta-
tutes of the ethics committees in these countries do not
foresee ethical review exemption. This study adhered to
the qualitative research review guidelines (RATS) [29].
Results
Advantages of the guideline
All interviewees expressed that the guideline’s advantages
outweighed the disadvantages. They stressed its impor-
tance and usefulness as a means of ensuring trial partici-
pants’ well-being, and data reliability and quality. Staff
appreciated the guideline’s framework while working in a
challenging environment.
‘There are advantages. All this allows us, firstly, to
obtain quality data; secondly, to respect the welfare
of study participants. So this is a necessary advan-
tage, plus it permits data standardisation relative to
other sites. To standardise the way people work
across sites, well these are all advantages. Now there
aren’t any drawbacks! There are just constraints’.
Investigator, male, Burkina Faso, Centre 5
Ninety percent of staff (55/60) across countries and
professional positions could not think of a single
Table 1 Characteristics of interviewed clinical trial staff
Kenya
(n = 17)
Ghana
(n = 13)
Burkina
Faso
(n = 16)
Senegal
(n = 14)
Role in study
Investigators
(n = 28)
8 4 8 8
Study coordinators
(n = 17)
5 6 3 3
Clinicians
(n = 10)
3 2 3 2
Professionals working
in QA (n = 5)
1 1 2 1
Gender
Female 9 4 3 4
Male 8 9 13 10
Clinical research experience (years)
0–2 1 4 2 1
3–5 2 3 4 2
6–8 6 0 5 3
9 and more 8 6 5 8
Study phase
Phase I (a + b) 10 3 10 3
Phase II 12 3 13 4
Phase III 13 10 13 8
Phase IV 4 7 9 3
Type of trial
Drug trial 15 8 16 11
Vaccine trial 14 10 13 9
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disadvantage or unnecessary step in working according to
the guideline. CT work is laborious and time-consuming,
but no time is lost due to guideline-related unnecessary
administration or repetitive steps. The entire administra-
tion process was regarded as an essential element of trials
and indispensable for quality. Some investigators (11/60),
mainly from English-speaking countries, mentioned the
high demand for documentation; 10 described it as a nui-
sance. However, all but one agreed that nothing should
be minimised or skipped in practice. The following quo-
tation is a representative experience of documentation
and repetition in clinical trials:
‘What happens, human as we are or practical as the
work may be, what happens if that result could not
be traced again? (. . .) when you see how important
what you would have thought was just too much
work becomes very useful. So yes, I sometimes, I
will agree with you that you would see some of the
work you are going over again and again and it
appears being repeated but generally, I think at the
close of the day, as much as you document the bet-
ter’. Quality Assurance professional, male, Ghana,
Centre 3
Three principal investigators and one clinician favoured
a risk-based approach, particularly for phase IV trials;
however, too few interviewed staff were involved in
phase IV trials to permit further investigation of this
topic.
‘Well time is definitely being lost on various things
but I guess deciding whether that is unnecessary is
the difficult thing. I mean, I think that there needs
to be a risk-based approach to the conduct of trials
if one is doing a new vaccine trial. You know vac-
cine is never been given to people before (. . .) But
on the other hand, if one is doing a phase IV trial of
medications that are already in use and one wants
to determine non-inferiority of a simpler regime, for
instance, then it would not be appropriate to apply
exactly the same rigor. And I think that this view is
starting to come into trials in Europe that one can
take a risk-based approach’. Investigator, male,
Kenya, Centre 1
Over-interpretation was never raised as an issue. How-
ever, the importance of training and experience in work-
ing with the guideline was emphasised.
Informed consent procedure
A third (18/60) of the interviewees, independent of coun-
try, position and language region, mentioned actively that
the guideline’s requirements for the informed consent
(IC) are unimplementable and too restrictive. Intervie-
wees (25/60) referred to major difficulties with IC,
including obtaining written and individual consent, find-
ing impartial witnesses for illiterates or legally acceptable
representatives for children, and guaranteeing voluntari-
ness and full understanding of the consent given. In the
perception of interviewees, GCP requires written consent
from a trial participant, which is difficult to apply to a
population with a high illiteracy rate and an oral culture,
where one’s word is highly valued and signatures or
thumb prints are associated with police punishment.
‘I think the first thing is that we have an oral tradi-
tion. And when I have to see someone to ask if he
wants to participate in my study, he says “yes,” I
say “okay yes” this is not enough, “read this paper,
and sign it.” I think that this is not traditional for
us. It can even happen that this brings trust issues
because he doesn’t understand why he must sign
something he has already agreed. So obviously, this
would have to be put back on the table and dis-
cussed again one day or another’. Investigator, male,
Burkina Faso, Centre 6
Trial participants in SSA are often shaped culturally
by a sense of collectivity. The importance of first
obtaining community consent from community and reli-
gious leaders was repeatedly stressed. Fulfilling the
GCP requirement of having an impartial witness pre-
sent for consent of illiterate trial participants can be
challenging when too few literate individuals are avail-
able or willing to serve as impartial witnesses. This
issue was mainly raised in Burkina Faso. To guarantee
impartiality, no payment is involved and an eligible
impartial witness may be required to serve for several
trial participants, potentially jeopardising the indepen-
dence of the witness.
Moreover, in SSA, documents confirming a child’s leg-
ally acceptable representative, as required by GCP, may
not be available. It is common for relatives to care for a
child in place of the biological parents, and thus, trial
staff struggle to include such children.
According to GCP, IC must be given voluntarily and in
full understanding of the benefits and risks of the trial.
Ensuring this is challenging when the language of the IC
form is highly technical and certain scientific words can-
not be translated into local languages. Interviewees sug-
gested treating consent as a continuous task whereby
essential information is repeated throughout the trial.
The high workload associated with this process, however,
caused interviewees to simultaneously question the
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feasibility of doing so. Trial staff also cautioned that
lengthy IC forms reduce comprehension among partici-
pants. A few staff members felt that IC served more to
protect the sponsor than to inform the trial participant.
‘Yes, we must alleviate [the informed consent]
because, in practice, we see that all this administra-
tion is not for the people, it is for the sponsor. The
sponsor does it to be safe, to be within his rights, in
case problems happen. So I, personally, say that, the
informed consent all that, that’s really for the spon-
sor or investigator, if there is a problem he could
say in court, “I have made this sign, that I will do
this”’. Investigator, male, Senegal, Centre 8
Yet, interviewees stressed the importance of IC and
asked for clear and applicable guidance in both lan-
guage regions. They perceived that GCP does not clarify
how to deal with listed IC issues and called them grey
areas.
‘Is there a better way we can do it? Can we use pic-
tures, can we use diagrams to convey the same mes-
sage yes, and meet all the essential elements for the
consent without having a 20 page document. Is
there a better way to do it?’ Investigator, male,
Kenya, Centre 2
While discussing IC difficulties often, the role of GCP
was addressed. Due to the consent difficulties, three inter-
viewees from French-speaking countries wanted a GCP
designed especially for Africa to outline a more relevant
and realistic IC process. However, most interviewees pre-
ferred using ICH-GCP as the globally applied guideline.
‘No I do not agree. No. What? Adapted to the con-
text? No. Research must be done the same way in
Europe, the USA and Africa. We need to create the
same conditions. Do you agree with me? You can-
not contextualise GCP, no. That’s not
research’. Investigator, male, Senegal, Centre 8
Oversight of compliance with guidelines
The importance of oversight by national authorities was
stressed; this topic came up less frequently than informed
consent challenges. This oversight seems to be missing
according to mainly Burkinabe interviewees, who wished
for well-functioning authorities. Some researchers experi-
enced challenges meeting GCP reporting requirements, as
the local authorities’ requirements were less comprehen-
sive. Coherence between GCP and authority requirements
was deemed important for increasing the guideline’s
usefulness.
‘And since they [authorities] gave their approval and
the study has started, we don’t come back to them
for information. They do not come to us either, so
there is a follow up problem. So it would be good,
if reports are made regularly. For them too, that
they can follow all we do. It’s good that you have
given your approval, but you have to follow
up’. Investigator, male, Burkina Faso, Centre 5
In the English-speaking African countries, some inter-
viewees complained about overcautious surveillance from
authorities and having many authorities involved in one
trial. Double ethical review from one national EC and
from the EC in the sponsors’ country was not challenged,
but interviewees criticised involving additional ECs as,
for example, institutional review boards on top. All
review committees have different reporting requirements,
which can be laborious to navigate while not adding to
the trial quality. One principal investigator in Kenya
compared the involvement of multiple ECs in a trial to
wearing several bicycle helmets: more do not increase
safety. Overcautious oversight also takes the form of
overly stringent reporting requirements, for example the
investigators have to report every serious adverse event
(SAE) individually to all national ECs, although the GCP
calls only for the sponsor to report suspected unexpected
serious adverse reactions (SUSARs). Five interviewees
claimed that the authorities would not spot the important
issues and miss the big picture in all of the information
collected. They perceived it important to align authority
requirements with GCP.
Discussion
Overall, interviewed CT staff in SSA found the GCP
guideline very helpful in guiding their daily work and
ensuring an international standard (Figure 1). Staff did
not complain about unnecessary administration, repeti-
tion or unnecessary details. We therefore conclude that
GCP is not being applied overcautiously from the per-
spective of visited CT teams. This finding was observed
consistently, independent of the country visited or the
staff level of interviewees. The result supports the general
opinion that GCP is an appropriate guideline for RLCs
[12, 16, 18–20]. It contradicts those authors claiming
that an adequate and applicable interpretation of GCP
was missing in RLCs [17, 19, 21]. Indeed, trial staff wor-
ried that a more pragmatic interpretation of GCP would
compromise quality.
Several factors might account for trial teams’ positive
accounts of working with GCP. Due to limited
resources and challenging working conditions, clinical
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research centres in RLCs may automatically take a more
pragmatic approach to GCP implementation than north-
ern countries. With less exposure to northern industrial
interpretations of GCP, they might be less likely to
adopt overprotective practices. Also CT staff might be
used to administration and questioning administrative
hurdles might not be a priority. Another explanation
could be the high frequency of vaccine trials in SSA.
Conducting vaccine trials is even more complex than
conducting drug trials. Whereas trials in the north are
conducted in hospitals and fully integrated into routine
work, the interviewees in SSA work in specialised clini-
cal research centres and might be more experienced and
skilled in research and in applying the guidelines. Per-
haps the guideline does not play an important role in
staffs’ CT routine; some spoke more about the protocol
than the guideline. Health staff coping with high
demands of guidelines in difficult working conditions
might adopt informal practices in order to deal with
their working realities [30]. This phenomenon, known
as ‘street-level bureaucracy’, could be another reason
why trial staff did not complain.
Despite an overall willingness to work with GCP,
one-third of the interviewees in both language regions
perceived GCP to be unsuitable for the IC process. It
surprised us to learn that in the staff’s experience, IC
challenges were more pertinent than the administrative
requirements. Perhaps it is not so unexpected, as the
guideline was developed according to different cultural
and educational characteristics of trial participants than
those found in SSA. IC difficulties are also mentioned
repeatedly in the literature [20, 24, 31, 32]. For exam-
ple, Kalabuanga et al. suggest changing the guideline to
permit trial inclusion of children without a legally
acceptable representative [33]. The length and technical
language of the consent form is a highly debated topic
in both the north and south, as is the view that its con-
tent serves mainly to protect sponsors [32, 34].
Figure 1 Summary of advantages and
challenges of working with International
Conference of Harmonization (ICH)-
Good Clinical Practice (GCP) in the
perspective of trial teams, ©evolve
communication gmbh.
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Based on the results and the discussion in the previous
paragraph, some interviewees seemed unaware that GCP
as a guideline allows for an adapted application. For
example, GCP does not explicitly require written consent.
Hence, if the local law does not require written consent,
deviation from the guideline is possible. Also GCP does
not forbid providing the participant information by
video, comic or tape. Deviations from the guideline for
other processes are possible if they are thoroughly
explained in the protocol.
Concrete guidance on how to best apply GCP in the
face of consent challenges was perceived to be missing by
interviewees. We had the impression that authorities were
not able to assist trial teams in mitigating their consent
challenges. The forthcoming integrated addendum to the
ICH-GCP E6 guideline [13] presents an opportunity to
refine the wording here.
The IC chapters in both the AVAREF-GCP and the
ICH-GCP are identical; however, in another chapter
AVAREF-GCP stresses that IC should be obtained in
accordance with national culture(s) and requirements.
The South African GCP (the only country in SSA to
have its own GCP guideline) differs from ICH-GCP by
requiring both written and verbal IC and by strongly
recommending community involvement and consultation
with community advisory groups. The South African
ethics guideline allows caregivers to consent whether the
minor does not have a legally acceptable representative
[35].
Some topics that were less frequently mentioned
should nevertheless not be neglected as they have also
been discussed in other publications discussing the appli-
cability of GCP. To maximise GCP’s helpfulness, inter-
viewees suggested that national authorities provide
adequate oversight and align their requirements with
GCP. Authorities in some SSA countries were only
recently established; thus, capacity building efforts must
be ongoing and collaboration between sponsor and
authorities prior to the study start is important [23].
Authorities must be capable of making contextualised
decisions [36].
Some trial staff perceived that authorities with sub-
stantial experience enforce GCP too rigorously and over-
protective. For example, comprehensive reporting of
SAEs to authorities is not required by GCP but accord-
ing to interviewees required by the authorities, which
leads to higher workloads for trial teams and an
unmanageably amount of safety data for the ECs [37].
J. Sing criticises the overprotective requirements of
South African authorities and asserts that although
authorities act with good intention, they end up
punishing the trial participant [38]. The lack of experi-
ence, resources and ability to decide on context-adapted
application of these authorities could be the reason for
this over-protectionism, which is driven by the good
intention of protecting the participant. An additional
challenge for national authorities is that they must com-
ply with health laws, which are often outdated in SSA
and may not include GCP. There are promising initia-
tives such as the African Medicines Regulatory Harmo-
nization Program, which aims to harmonise medicines
regulations [39].
There are some limitations to this study. Although
our research covered various geographical and language
regions, findings might not be true for all clinical
research centres in SSA as the sample size was small
due to the qualitative approach. Data were collected by
a female Swiss scientist, which might have contributed
to a degree of bias, as monitoring and auditing visits
are often carried out by foreigners. Another limitation is
that we do not know the extent to which CT teams fol-
low GCP in practice, as the study was interview-based
and processes were not checked. We deliberately
avoided testing the interviewees’ GCP knowledge
because we wanted to provide an environment con-
ducive to open expression. These limitations are some-
what mitigated by the fact that all centres visited have
long-standing experience and have been repeatedly mon-
itored and audited.
Conclusion
According to the interviewed trial teams, GCP is a
helpful and important guideline for working in chal-
lenging environments. One-third of the interviewees
found the application of GCP for informed consent to
be challenging. Overall, GCP is perceived to be effi-
ciently applied and appropriate. Applying GCP in an
adapted manner and using the flexibility offered by the
guideline might help to avoid consent challenges in
future.
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